Diffusely Increased Bone Marrow Uptake on DOTATATE PET/CT Due to PRRT-related Myelodysplasia Syndrome
We report an unusual imaging finding on DOTATATE PET/CT in a patient with prior 177Lu-DOTATATE treatment for metastatic small bowel neuroendocrine tumor. Five years post-treatment follow-up DOTATATE PET/CT for fatigue and back pain showed new diffusely increased bone marrow uptake in addition to focal uptake corresponding to known metastases. Faint/mild bone marrow uptake of DOTATATE can be seen due to the presence of SST-2 receptor on CD-34 hematopoietic progenitor cells in the marrow, but diffusely increased marrow uptake, as in this case, was not deemed physiologic and was concerning for marrow pathology. Subsequent bone marrow biopsy confirmed therapy-related myelodysplastic syndrome (t-MDS).
Authors
- Ekaterina Menshikova (ORCID: https://orcid.org/0000-0001-8228-8236)
- Chenxi Wu (ORCID: https://orcid.org/0000-0002-2908-9841)
- Amol Takalkar
Institutions
- Emory University (US)
- Society of Nuclear Medicine and Molecular Imaging (US)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1097/rlu.0000000000006095
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00